RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:213625

Leiomyosarcoma of the corpus uteri

low confidenceDisorder

Publications

3,980

Trials

31

Interventional, condition-specific

Researchers

1,332

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

Leiomyosarcoma of the corpus uteri is a rare, malignant, mesenchymal tumor of smooth muscle origin characterized, histologically, by spindle and/or pleomorphic cells, often forming disorganized fascicles, with tumor cell necrosis and, macroscopically, by a large, soft, usually intramural mass with irregular borders and necrotic and hemorrhagic areas, located in the uterus. Presenting signs and symptoms typically include dysfunctional vaginal bleeding, vaginal discharge, palpable pelvic mass and/or pelvic pain/pressure. Changes in bowel habits, frequent or painful urination and hematuria may also be associated.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (16)

Uterine Leiomyosarcoma · body of uterus leiomyosarcoma · corpus uteri leiomyosarcoma · leiomyosarcoma - uterus · leiomyosarcoma of body of uterus · leiomyosarcoma of corpus uteri · leiomyosarcoma of the body of uterus · leiomyosarcoma of the corpus uteri · leiomyosarcoma of the uterine body · leiomyosarcoma of the uterine corpus · leiomyosarcoma of the uterus · leiomyosarcoma of uterine body · leiomyosarcoma of uterine corpus · leiomyosarcoma of uterus · uterine body leiomyosarcoma · uterine corpus leiomyosarcoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    3,980 matched papers (2,268 in last 10 years) Source

  3. Phenotype characterisedNot found

    No HPO disease–phenotype associations via Monarch for these Mondo IDs

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    31 matched on ClinicalTrials.gov (3 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

21

Drugs / clinical candidates · MONDO_0016262

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

3,980

3,980 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

3,980 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

2,268 in the last 10 years · low confidence

Phrase hits: 3,980 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,332

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Hayashi T9 papers · 2026

    2Cancer Medicine, National Hospital Organization Kyoto Medical Centre; 3Medical R&D Promotion Project, The Japan Agency for Medical Research and Development (AMED), Tokyo, Japan.

    Papers in Europe PMC
  2. 02
    Konishi I9 papers · 2026

    1Department of Obstetrics and Gynecology, National Hospital Organization Kyoto Medical Centre, Japan.

    Papers in Europe PMC
  3. 03
    Abiko K6 papers · 2024

    1Department of Obstetrics and Gynecology, National Hospital Organization Kyoto Medical Centre, Japan.

    Papers in Europe PMC
  4. 04
    Lee B4 papers · 2026

    Surgical Oncology, Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA. byrnelee@stanford.edu.

    Papers in Europe PMC
  5. 05
    Nucci MR4 papers · 2026

    Department of Pathology, Brigham and Women's Hospital/Harvard Medical School, Boston, MA.

    Papers in Europe PMC
  6. 06
    Wang Y4 papers · 2026

    Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.

    Papers in Europe PMC
  7. 07
    Chen Z3 papers · 2025

    Department of Obstetrics and Gynecology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

    Papers in Europe PMC
  8. 08
    Chiang S3 papers · 2026

    Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: chiangs@mskcc.org.

    Papers in Europe PMC
  9. 09
    Colombo N3 papers · 2026

    Department of Gynecology, European Institute of Oncology (IEO) IRCCS, Milan, Italy.

    Papers in Europe PMC
  10. 10
    Croce S3 papers · 2026

    Institut Bergonié, Comprehensive Cancer Center, Bordeaux, France.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

31

interventional trials for this specific condition

31 interventional trials matched this specific condition name; 3 currently recruiting in our sample. 109 trials are registered for leiomyosarcoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026

31 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 96.1th percentile).

low confidence · 96.1th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

31 interventional trials matched after quoted-phrase search and title/condition post-filter.

Broader category: leiomyosarcoma

109

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Observational and natural-history studies

3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

None of the matched observational studies is currently listed as recruiting.

Open the complete matched search on ClinicalTrials.gov

General rare disease registries you may be eligible for

These studies enroll across many rare conditions. They are not counted as evidence that anyone is studying this specific disease.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 3 · after dedupe 3 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 3 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (3)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Leiomyosarcoma of the corpus uteri — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Leiomyosarcoma of the corpus uteri" OR "Leiomyosarcoma of corpus uteri" OR "Uterine Leiomyosarcoma" OR "body of uterus leiomyosarcoma" OR "body of the uterus leiomyosarcoma" OR "corpus uteri leiomyosarcoma" OR "leiomyosarcoma - uterus" OR "leiomyosarcoma of body of uterus" OR "leiomyosarcoma of the body of the uterus" OR "leiomyosarcoma of the body of uterus" OR "leiomyosarcoma of the uterine body" OR "leiomyosarcoma of uterine body" OR "leiomyosarcoma of the uterine corpus" OR "leiomyosarcoma of uterine corpus" OR "leiomyosarcoma of the uterus" OR "leiomyosarcoma of uterus" OR "uterine body leiomyosarcoma" OR "uterine corpus leiomyosarcoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Leiomyosarcoma of the corpus uteri" OR "Leiomyosarcoma of corpus uteri" OR "Uterine Leiomyosarcoma" OR "body of uterus leiomyosarcoma" OR "body of the uterus leiomyosarcoma" OR "corpus uteri leiomyosarcoma" OR "leiomyosarcoma - uterus" OR "leiomyosarcoma of body of uterus" OR "leiomyosarcoma of the body of the uterus" OR "leiomyosarcoma of the body of uterus" OR "leiomyosarcoma of the uterine body" OR "leiomyosarcoma of uterine body" OR "leiomyosarcoma of the uterine corpus" OR "leiomyosarcoma of uterine corpus" OR "leiomyosarcoma of the uterus" OR "leiomyosarcoma of uterus" OR "uterine body leiomyosarcoma" OR "uterine corpus leiomyosarcoma"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 31 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"leiomyosarcoma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (3980) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-27T09:35:31.330Z